Enliven Therapeutics Inc
ELVNHealthcare|Biotechnology|USA
$51.09
-1.09 (-2.09%)
Tangible Book
$7.45
About
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Stock Price
+124.3%(1Y)
Pipeline Summary
4 total trials4
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Active: 2Recruiting: 2
Active Trials (4)
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879HER2 Mutant Non-small Cell Lung Cancer
Phase 1Active
Enrollment: 198 participants
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia
Phase 1Recruiting
Enrollment: 250 participants
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
NCT06787144CML (Chronic Myelogenous Leukemia)
Phase 1Recruiting
Enrollment: 21 participants
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738HER2-positive Breast Cancer
Phase 1Active
Enrollment: 275 participants
BioScore
3.8/10
Cautious
Ownership
Recent Insider Trades
Kunkel Lori AnneSELL
2026-07-0610,000 shares @ $50.49
ORBIMED ADVISORS LLCSELL
2026-06-22860,123 shares @ $45.36
Hohl BenjaminSELL
2026-06-176,018 shares @ $43.8
Collins Helen LouiseSELL
2026-06-175,000 shares @ $43.8
ORBIMED ADVISORS LLCSELL
2026-06-15281,408 shares @ $45.02
Recent News
2026-07-09 11:01:25
2026-07-09 00:04:49
2026-07-01 14:39:27
2026-06-29 16:02:19
2026-06-24 00:34:50
Data last updated: Jul 13, 2026, 12:41 PM